Novartis ruling: Alone, but correct?

On April 1, the Indian Supreme Court rejected the attempt by Novartis, the Swiss pharmaceutical company, to patent a new version of the anti-leukaemia drug Glivec. The latest verdict follows previous rulings that granted compulsory licences to an Indian generic drug manufacturer for Nexavar, a drug used to treat kidney cancer, patented by Bayer. These rulings raise five important questions.

Read Full Story>>